Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

Publisher: John Wiley & Sons Inc

E-ISSN: 2045-7634|4|6|864-870

ISSN: 2045-7634

Source: Cancer Medicine, Vol.4, Iss.6, 2015-06, pp. : 864-870

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content